| Title: |
Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. |
| Authors: |
Fizazi, K; Chi, KN; de Bono, JS; Gomella, LG; Miller, K; Rathkopf, DE; Ryan, CJ; Scher, HI; Shore, ND; De Porre, P; Londhe, A; McGowan, T; Pelhivanov, N; Charnas, R; Todd, MB; Montgomery, B |
| Contributors: |
De Bono, Johann |
| Publisher Information: |
ELSEVIER SCIENCE BV |
| Publication Year: |
2017 |
| Collection: |
The Institute of Cancer Research (ICR): Publications Repository |
| Subject Terms: |
Humans; Hyperglycemia; Weight Gain; Prednisone; Antineoplastic Combined Chemotherapy Protocols; Time Factors; Adult; Aged; 80 and over; Middle Aged; Male; Prostatic Neoplasms; Castration-Resistant; Abiraterone Acetate |
| Description: |
BACKGROUND: Abiraterone acetate (AA) is the prodrug of abiraterone, which inhibits CYP17A1 and testosterone synthesis and prolongs the survival of patients with metastatic castration-resistant prostate cancer (mCRPC). AA plus prednisone (P) (AA+P) is approved for the treatment of patients with mCRPC. OBJECTIVE: To investigate whether long-term use of low-dose P with or without AA leads to corticosteroid-associated adverse events (CA-AEs) in mCRPC patients. DESIGN, SETTING, AND PARTICIPANTS: The study included 2267 patients in COU-AA-301 and COU-AA-302. We used an inclusive Standardized MedDRA Queries-oriented approach to identify 112 preferred terms for known CA-AEs, and assessed the incidence of CA-AEs during 3-mo exposure intervals and across all P exposure levels. INTERVENTION: All 2267 patients received 5mg of P twice daily, and 1333/2267 received AA (1g) plus P. RESULTS AND LIMITATIONS: The CA-AE incidence after any P exposure was 25%, 26%, and 23% for any grade, and 5%, 5%, and 4% for grade ≥3 CA-AEs for all patients and the AA+P and P alone groups, respectively. The most common any-grade CA-AEs were hyperglycemia (7.4%, 7.8%, and 6.9% for all patients, AA+P, and P alone, respectively) and weight increase (4.3%, 3.9%, and 4.8%, respectively). When assessed by duration of exposure (3-mo intervals up to ≥30 mo), no discernable trend was observed for CA-AEs, including hyperglycemia and weight increase. The investigator-reported study discontinuation rate due to CA-AEs was 11/2267 (0.5%), and one patient had a CA-AE resulting in death. CONCLUSIONS: Low-dose P given with or without AA is associated with low overall incidence of CA-AEs. The frequency of CA-AEs remained low with increased duration of exposure to P. PATIENT SUMMARY: We assessed adverse events in patients with metastatic castration-resistant prostate cancer during long-term treatment with a low dose of a corticosteroid. We found that long-term treatment with this low-dose corticosteroid is safe and tolerable. |
| Document Type: |
article in journal/newspaper |
| File Description: |
Print-Electronic; 444; application/pdf |
| Language: |
English |
| ISSN: |
1873-7560; 0302-2838 |
| Relation: |
European urology, 2016, 70 (3), pp. 438 - 444; https://repository.icr.ac.uk/handle/internal/453 |
| DOI: |
10.1016/j.eururo.2016.02.035 |
| Availability: |
https://doi.org/10.1016/j.eururo.2016.02.035; https://repository.icr.ac.uk/handle/internal/453 |
| Accession Number: |
edsbas.460CB492 |
| Database: |
BASE |